Cite
HARVARD Citation
Riedl, M. et al. (2018). Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study. Allergy. 73 (9), pp. 1871-1880. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Riedl, M. et al. (2018). Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study. Allergy. 73 (9), pp. 1871-1880. [Online].